A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions

Ascentage Pharma (6855.HK) is a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. The company focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.

Learn More

Targeting Key Regulatory Proteins
in Apoptotic Pathways

BCL2

Bcl2

MDM2

MDM2-p53

Global Clinical Trials

Learn More

San Antonio, TX

San Diego, CA

Rochester, MN

Ann Arbor, MI

Cleveland, OH

Philadelphia, PA

Baltimore, MD

Beijing

Suzhou

Guangzhou

Nedlands, AU

Camperdown, AU